Industry Briefs: Jan. 30, 2012
A roundup of other company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.
Company News
Aptar Pharma has opened a new manufacturing site near Mumbai, India. Read More
FDA has approved Pfizer’s Inlyta (axitinib), a kinase inhibitor for treating advanced renal cell carcinoma. Read More
FDA has approved Roche’s Erivedge (vismodegib) capsule for treating advanced basal cell carcinoma. Read More
Lpath has temporarily suspended dosing of iSONEP, for treating age-related macular degeneration, in clinical trials due to cGMP compliance issues at the contract fill–finish source. Read More
Roche has formally issued an offer to acquire all outstanding shares of Illumina for $44.50 per share in cash, or an aggregate of approximately $5.7 billion. Read More
Royal DSM and Indoco Remedies have formed a commercialization agreement for eight APIs. Read More
Valeant Pharmaceuticals has withdrawn its offer to acquire ISTA Pharmaceuticals for $7.50 per share in cash. Read More
Watson Pharmaceuticals announced plans to establish a New Jersey-based R&D technology center to support generic-drug pharmaceutical product development. Read More
People News
GlaxoSmithKline has announced changes to its board of directors. Read More
Octagon Research Solutions has appointed Gina L. Schmidt to manage the company’s global regulatory services division. Read More
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
